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AbstrAct
Objective It is unclear if activation of inflammatory 
pathways regulates proprotein convertase subtilisin-kexin 
type 9 (PCSK9) levels.
Approach We evaluated (1) the temporal course of serum 
PCSK9 during hospitalisation following acute coronary 
syndrome and associations with markers of inflammation 
(leucocyte counts, interleukin (IL)-6, C-reactive protein) 
and lipid levels and (2) the effect of inhibition of IL-6 
signalling with the IL-6 receptor antibody tocilizumab on 
PCSK9 levels in a randomised, double-blind, placebo-
controlled trial release in patients with non-ST-elevation 
myocardial infarction.
Results Serum PCSK9 increased during the acute 
phase and this response was modestly associated with 
neutrophil counts (r=0.24, p=0.009) and presence of 
hypercholesterolaemia (r=0.019, p=0.045), but was not 
modified by tocilizumab. However, a modifying effect of 
tocilizumab on PCSK9 levels was observed in patients 
with hypercholesterolaemia (p=0.024, repeated measures 
analysis of variance) and this effect was strongly 
correlated with the decrease in neutrophils (r=0.66, 
p=0.004).
Conclusions Our study suggests that patients with 
a more atherogenic profile may benefit from anti-IL-6 
therapy with regard to PCSK9.
Trial registration number NCT01491074.
InTROduCTIOn
The enzyme proprotein convertase subtili-
sin-kexin type 9 (PCSK9) binds to the 
hepatic low-density lipoprotein (LDL) 
receptor, thereby inhibiting recycling of this 
receptor resulting in attenuated removal of 
LDL cholesterol (LDL-C) from the circula-
tion.1 The importance of PCSK9 for LDL-C 
homeostasis is illustrated in individuals with 
loss-of-function or gain-of-function muta-
tions in this enzyme leading to hypocho-
lesterolaemia or hypercholesterolaemia, 
respectively, with dramatic effects on the 
incidence of atherosclerotic disease.2 Also, 
recent studies have shown that anti-PCSK9 
therapies markedly reduce LDL-C levels 
leading to lower incidence of adverse cardi-
ovascular disease outcomes in high-risk 
patients with hyperlipidaemia.1 3 4 
PCSK9 is secreted by the liver and circu-
lating levels could therefore be readily 
assessable parameter of PCSK9 status.5 In 
the general population, we recently found 
a 47% higher risk for myocardial infarction 
(MI) in individuals with high (ie, fourth quar-
tile) serum PCSK9.6 There are limited data 
on PCSK9 in patients with acute coronary 
syndrome (ACS), apart from a small study 
with few, poorly matched, controls showing 
elevated levels.7 In a large study of ACS, high 
Key questions
What is already known about this subject?
 ► The association between proprotein convertase 
subtilisin-kexin type 9 (PCSK9) and inflammation is 
unclear.
What does this study add?
 ► Serum PCSK9 was not modified by anti-inflammato-
ry treatment and not associated with change in in-
flammatory markers suggesting a limited influence 
of inflammation on PCSK9.
 ► In patients with an established diagnosis of hy-
percholesterolaemia, tocilizumab blunted the 
non-ST-elevation  myocardial infarction-associated 
PCSK9 increase and this was strongly correlated 
with a decrease in neutrophil numbers.
How might this impact on clinical practice?
 ► Patients with a more atherogenic profile may ben-
efit from anti-interleukin-6 therapy with regard to 
PCSK9 levels.
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PCSK9 levels were associated with presence of hypercho-
lesterolaemia, lipid-lowering therapy and higher C-reac-
tive protein (CRP) levels in the acute phase, but not with 
1-year mortality.8 Other studies have found higher PCSK9 
levels to be associated with ischaemic events9 and severity 
of coronary lesions,10 suggesting that targeting of PCSK9 
could have a place in the management of high LDL-C 
and ACS. Several studies link PCSK9 to inflammation, 
independent of lipids. In vitro, PCSK9 enhances inflam-
matory pathways in macrophages,11 augments oxidised 
LDL-induced apoptosis in endothelial cells12 and, in vivo, 
PCSK9 is expressed in human atherosclerotic plaques13 
and circulating levels correlate with platelet reactivity9 
and coronary plaque inflammation.14 However, whether 
activation of inflammatory pathways regulates PCSK9 
levels is still incompletely understood.
Interleukin (IL)-6 is a pleiotropic cytokine and 
centrally involved in stimulating the acute phase 
response and orchestrating leucocyte infiltration 
during tissue injury.15 IL-6 has been suggested to be a 
major player in ACS,16 and we recently demonstrated 
that the humanised anti-IL-6 receptor (IL-6R) antibody, 
tocilizumab, had beneficial effects on inflammation (ie, 
CRP) and troponin T (TnT) release in patients with 
non-ST-elevation myocardial infarction (NSTEMI).17 
To further examine the regulation of PCSK9 we anal-
ysed (1) serum PCSK9 in NSTEMI compared with 
healthy controls, (2) the temporal course of PCSK9 
during hospitalisation relative to healthy control levels 
and associations with markers of inflammation, (3) 
effect of inhibition of IL-6 signalling with tocilizumab 
on PCSK9 levels in a randomised, double-blind, place-
bo-controlled trial, and (4) if the effect of IL-6 inhibi-
tion differs depending on cholesterol status.
MATeRIAls And MeTHOds
This study was part of a randomised, double-blind, place-
bo-controlled trial (n=117) designed to evaluate the effect 
of a single dose of the anti-IL-6R antibody tocilizumab in 
NSTEMI ( ClinicalTrials. gov, NCT01491074), approved by 
the Regional Ethical Committee, conducted according to 
the Helsinki Declaration with written informed consent 
provided by all patients.17
The study design has previously been described.17 
Briefly, patients between 18 and 80 years of age with 
NSTEMI presumed to be caused by coronary artery 
disease (CAD) were eligible for inclusion. Major exclu-
sion criteria were clinically significant heart disease 
other than CAD, clinical instability, inflammatory 
diseases or drugs affecting inflammation, contraindica-
tions to tocilizumab and any condition that could inter-
fere with protocol adherence. Patients were included 
on the day of scheduled coronary angiography. After 
baseline blood sampling, patients received an intra-
venous infusion of tocilizumab 280 mg or matching 
placebo (saline) prior to coronary angiography. After 
study drug administration and coronary angiography, 
six blood samples were obtained during the first 3 days 
of hospitalisation (day 1: evening; day 2: morning, 
afternoon, evening; day 3: morning, afternoon). For 
comparison, serum was collected from 27 apparently 
healthy subjects based on disease history and normal 
levels of CRP, recruited from the hospital staff for 
acquaintances.
serum PCsK9 and biochemical analysis
Peripheral venous blood was drawn into pyrogen-free 
tubes without any additives. After clotting at room 
temperature, the tubes were centrifuged at 2100 g 
for 15 min, and serum was stored at –80°C. Serum 
PCSK9 was measured in duplicate by enzyme immu-
noassay with antibodies obtained (Catalogue number 
DY3888) from R&D Systems (Minneapolis, MN) in a 
384-well format using a combination of a SELMA (Jena, 
Germany) pipetting robot and a BioTek (Winooski, 
VT, USA) dispenser/washer. Absorption was read at 
450 nm with wavelength correction set to 540 nm using 
an ELISA plate reader (BioTek). The intra-assay and 
interassay coefficients of variations were 4.2% and 2.5% 
for PCSK9. Serum IL-6, high sensitivity (hs)CRP, hsTnT 
and lipid parameters were measured as reported previ-
ously.17
statistical analysis
Comparison of PCSK9 levels (log transformed) between 
controls and patients with NSTEMI was performed 
using linear regression adjusting for age and body mass 
index (BMI). Comparison of baseline demographics 
and biochemical measures between the treatment 
groups was performed using unpaired t-tests, Mann-
Whitney U tests, Χ2 test for independence or the Fish-
er’s exact test depending on variable type and distri-
bution. Univariate associations between PCSK9 and 
demographic, inflammatory and biochemical measures 
in patients with NSTEMI were assessed with Spearman’s 
rank correlation. In cases where adjustments for study 
treatment and/or statin use were performed, partial 
correlation (using log-transformed value where appro-
priate) coefficients are reported. Treatment effects on 
PCSK9 (log transformed) were assessed using repeated 
measures analysis of variance (ANOVA) with baseline 
levels and statin use as covariates. Using this model, 
the group effect will indicate a treatment effect on log 
PCSK9 levels while the group*time interaction indi-
cates a different temporal course. This procedure uses 
an unstructured covariance matrix in SPSS. To eval-
uate the effects of hypercholesterolaemia on treatment 
responses we first calculated the area under the curve 
(AUC) during hospitalisation (baseline to day 3) for 
PCSK9 using the trapezoidal rule. We then compared 
the treatment and hypercholesterolaemia groups 
(ie, four groups, placebo and tocilizumab with and 
without hypercholesterolaemia) with Kruskal-Wallis 
followed by comparisons between individual groups 
with Mann-Whitney U tests. Treatment effects were 
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further analysed within the groups of patients with and 
without hypercholesterolaemia by repeated measures 
ANOVA, adjusting for baseline values and statin treat-
ment. P values are two sided and considered significant 
when <0.05. Statistical analysis was performed with 
SPSS V.25.0.
ResulTs
PCsK9 in nsTeMI
We first compared serum PCSK9 in our patients with 
NSTEMI (n=117, mean±SD age 60±9 years, 12% women, 
BMI 28.1±4.0 kg/m2, 28% smokers, creatinine 78±16 
µmol/L) with healthy controls (n=27, age 66±12 years 
(p=0.002), 14% women (p=0.79), BMI 24.9±2.7 kg/
m2 (p<0.001), 28% smokers (p=1.0), creatinine 79±12 
µmol/L (p=0.96)), adjusting for differences in age and 
BMI, and found that patients with NSTEMI had markedly 
elevated levels (figure 1).
effect of tocilizumab on PCsK9
Details regarding study population, clinical characteristics 
and dropouts for all patients are previously described17 
and are briefly presented in table 1 showing no differ-
ences between the treatment groups.
No correlations between demographic and biochemical 
measures in table 1 and baseline PCSK9 were detected, 
except a positive correlation with BMI after adjustment 
for statin use. As shown in figure 2, no overall treatment 
effect was observed (p=0.621), although an interaction 
between treatment and time was observed (p=0.025). 
In both groups an increase in PCSK9 was observed 
during the acute phase with the highest levels towards 
the end of the second day, followed by a decline with 
levels similar to baseline in the placebo group. However, 
PCSK9 levels remained elevated compared with healthy 
controls throughout the observation period in both treat-
ment groups. No significant modifying effect of percuta-
neous coronary intervention (PCI) was observed on the 
temporal course of PCSK9 (figure 2).
Associations between PCsK9 and inflammatory measures 
during the acute phase in the total study population
To evaluate the association between the temporal 
response in PCSK9 and inflammatory markers and lipids, 
we correlated the AUC for PCSK9 and AUC for leucocyte 
counts, lipid levels (total C and LDL-C), CRP, IL-6 or TnT 
as well hypercholesterolaemia defined as patients with an 
established diagnosis of hypercholesterolaemia according 
to prevailing Norwegian guidelines18 prior to inclusion 
(total C >5 mmol/L and/or LDL-C >3 mmol/L). A positive 
correlation between PCSK9 and leucocyte counts (r=0.27, 
p=0.004), neutrophil counts (r=0.22, p=0.018) and pres-
ence of hypercholesterolaemia (r=0.18, p=0.048), but 
not inflammatory markers or lipid levels, was detected. 
Leucocyte and neutrophil counts decreased during 
tocilizumab treatment17 and when adjusting for study 
treatment, the association between AUC for PCSK9 and 
leucocytes (r=0.20, p=0.036) and hypercholesterolaemia 
(r=0.21, p=0.031) persisted. Further adjustment for statin 
use revealed similar results (leucocytes, r=0.19, p=0.042; 
hypercholesterolaemia, r=0.21, p=0.024). No other corre-
lations were detected when adjusting for study treatment 
and/or statin use.
Modifying effect of hypercholesterolaemia on the effect of 
tocilizumab on PCsK9
We further explored the association between PCSK9 
and hypercholesterolaemia. Comparing the AUC during 
hospitalisation for PCSK9 in groups stratified by treat-
ment and presence of hypercholesterolaemia revealed 
a higher AUC in patients with hypercholesterolaemia 
treated with placebo (figure 3A). This association was 
further explored by comparing the temporal course of 
PCSK9 (figure 3B), adjusting for statin use and base-
line PCSK9, and revealed no effect of tocilizumab on 
PCSK9 in patients without hypercholesterolaemia (top 
panel, p=0.97). In contrast, a significant treatment effect 
(bottom panel, p=0.025) was detected in patients with 
hypercholesterolaemia with a blunted increase in PCSK9 
in patients treated with tocilizumab. Evaluation of asso-
ciations with leucocyte counts, lipid levels, CRP, IL-6 or 
TnT within the stratification cholesterol groups revealed 
that the response in PCSK9 AUC strongly correlated with 
the AUC for leucocytes (r=0.77, p<0.001) and neutro-
phils (r=0.72, p=0.001), which both decreased during 
tocilizumab treatment, also after adjusting for statin use 
(leucocytes r=0.64, p=0.008; neutrophils r=0.60, p=0.015), 
in patients with hypercholesterolaemia treated with tocili-
zumab, but not those treated with placebo (figure 4) .
dIsCussIOn
We studied the effect of the anti-IL-6R antibody tocili-
zumab on serum PCSK9 levels in patients with NSTEMI. 
Figure 1 Tukey plot of serum proprotein convertase 
subtilisin-kexin type 9 (PCSK9) in healthy controls (CTR; 
n=27) and patients with non-ST-elevation myocardial 
infarction (NSTEMI; n=117) on admission. P values are 
adjusted for age and body mass index (BMI). 
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Patients with NSTEMI had increased serum PCSK9 
compared with controls and levels increased on the first 
2 days during hospitalisation with no differences between 
the treatment groups. However, stratifying patients 
revealed that tocilizumab attenuated the response in 
PCSK9 during hospitalisation in patients with an estab-
lished diagnosis of hypercholesterolaemia prior to 
NSTEMI and study enrolment.
A recent study reported elevated PCSK9 in patients 
with ACS compared with healthy controls, although 
the control group was reported as ‘young’ and no age 
was given.7 Our findings demonstrate that patients with 
NSTEMI are characterised by increased PCSK9 levels 
compared with a more evenly matched healthy control 
group. Almontashiri et al reported that PCSK9, evaluated 
on admission, was elevated in acute MI compared with 
CAD without MI or with prior MI, suggesting a transient 
increase during ACS.19 However, our longitudinal assess-
ment argues against differences between patients with 
ACS at admission and patients with stable CAD as we 
Table 1 Baseline characteristics according to treatment group and association with PCSK9
Placebo
(n=59)
Tocilizumab
(n=58)
Between groups
P values
PCSK9†
R
PCSK9‡
R
Age (years) 60.1±9.9 59.8±7.7 0.859 −0.03 −0.16
Female gender 5 (8.5%) 9 (15.5%) 0.364 0.02 0.00
BMI (kg/m2) 27.4±4.4 28.8±3.3 0.055 −0.08 0.25*
Hypertension 17 (28.8%) 26 (44.8%) 0.109 −0.09 0.07
Hypercholesterolaemia 13 (22.0%) 17 (29.3%) 0.491 0.06 0.15
Diabetes type 2 10 (16.9%) 10 (17.2%) 1.0 −0.06 0.01
Smoking (previous or current) 40 (67.8 %) 35 (61.4%) 0.599 0.06 0.08
Heart rate (beats/min) 66±13 66±10 0.770 −0.08 0.02
SBP (mm Hg) 137±18 140±18 0.389 −0.06 0.02
DBP (mm Hg) 81±12 83±12 0.273 −0.05 0.08
PCI 47 (79.7%) 41 (70.7%) 0.367 −0.04 0.02
CABG 7 (11.9%) 6 (10.3%) 1.0 0.00 0.12
Medical treatment 5 (8.5%) 11 (19.0%) 0.167 0.05 −0.14
GRACE score 92 (75, 105) 86 (72, 97) 0.168 0.00 −0.16
Biochemistry
  Creatinine (µmol/L) 76 (69, 90) 76 (66, 83) 0.260 −0.10 0.02
  Leucocytes (×109/L) 7.3 (5.9, 9.2) 7.9 (5.9, 9.3) 0.406 0.12 0.02
  Neutrophils (×109/L) 4.5 (3.4, 6.0) 5.1 (3.4, 6.3) 0.471 0.08 0.04
  Interleukin-6 (pg/mL) 2.2 (1.1, 4.6) 2.7 (1.2, 8.7) 0.185 0.02 −0.10
  C-reactive protein (mg/L) 2.5 (1.0, 8.3) 2.7 (1.5, 4.7) 0.458 0.02 0.01
  Troponin T (ng/L) 192 (71, 571) 128 (53, 749) 0.965 0.05 0.05
  Total cholesterol (mmol/L) 5.3 (4.5, 5.9) 4.9 (4.2, 5.7) 0.279 −0.02 0.10
  LDL cholesterol (mmol/L) 3.2 (2.8, 3.8) 3.0 (2.3, 3.6) 0.149 −0.09 0.09
Medication at baseline
  Aspirin 59 (100%) 57 (98.3%) 0.496 0.04 0.06
  Clopidogrel 32 (54.2%) 32 (55.2%) 1.0 −0.02 −0.06
  Ticagrelor 27 (45.8%) 26 (44.8%) 1.0 0.02 0.06
  Low molecular weight heparin 54 (91.5%) 51 (89.5%) 0.952 0.01 −0.03
  Beta blocker 45 (76.3%) 45 (77.6%) 1.0 −0.05 −0.05
  Statin 53 (89.8%) 53 (91.4%) 1.0 0.14 – 
*P<0.01. 
†Spearman correlation.
‡Partial correlation adjusting for statin use. Categorical data are given as n (%). Continuous data are expressed as mean±SD or median 
(25th, 75th percentiles) and were compared with unpaired parametric or non-parametric tests depending on distribution. 
BMI, body mass index; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; GRACE, Global Registry of Acute Coronary 
Events; LDL, low-density lipoprotein; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin-kexin type 9; SBP, 
systolic blood pressure.
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observed similar levels of PCSK9 at baseline and at 3 and 
6 months of follow-up. Nonetheless, we also show that 
PCSK9 displayed a transient response during hospitalisa-
tion with a maximum increase on day 2, with no relation 
to PCI, in agreement with the only previous study evalu-
ating the temporal course in ACS.10
Clinical and experimental studies show that systemic 
inflammation increases the expression of PCSK920 and 
that PCSK9 increases with severe traumatic injury.21 In 
line with our clinical data, plasma PCSK9 peaked at 2 
days in an acute MI rat model22 in parallel with enhanced 
hepatic mRNA expression of PCSK9 and the transcrip-
tion factors HNF1α and SREBP-2, which may regulate 
the expression of CRP23 and promote inflammation in 
vascular cells,24 respectively. However, we were unable 
to identify any correlation between PCSK9 and CRP or 
IL-6 levels, although a modest association with leucocyte 
numbers during hospitalisation was observed. Moreover, 
treatment with an anti-IL-6R antibody, which markedly 
attenuates the acute phase reactants (eg, decreases CRP, 
leucocyte counts), had no effect on PCSK9 levels in the 
study population as a whole. A lack of association between 
PCSK9 and CRP has been reported in two larger ACS 
populations,8 10 and stratification by use of lipid lowering 
therapy revealed significant associations in non-users in 
one study.8
In the largest study of PCSK9 in ACS, Gencer et al iden-
tified hypercholesterolaemia as a major determinant of 
PCSK9.8 In the present study, patients with medical history 
of hypercholesterolaemia had an enhanced response in 
PCSK9 during the acute phase, and notably, tocilizumab 
had a significant attenuating effect on serum PCSK9 in 
these but not in the other patients. In addition to its 
ability to inhibit IL-6-induced CRP production, blocking 
IL-6 signalling with tocilizumab is associated with tran-
sient leucopenia/neutropenia,25 as also found in the 
present NSTEMI study.17 However, while the leucopenia 
during hospitalisation was similar in patients treated 
with tocilizumab, irrespective of hypercholesterolaemia 
status, we observed a strong correlation between PCSK9 
Figure 2 Serum PCSK9 in patients with non-ST-
elevation myocardial infarction (NSTEMI) receiving placebo 
(n=59) or tocilizumab (n=58) during hospitalisation and at 
3 and 6 months of follow-up. Circles represent geometric 
back-transformed estimated marginal means and 95% CIs, 
respectively. *P<0.05; **P<0.01; ***P<0.001 versus baseline 
(BL). The grey area and line represent the geometric mean 
and 95% CI for healthy controls. AFN, afternoon; ANOVA, 
analysis of variance; EVE, evening; MO, morning; PCSK9, 
proprotein convertase subtilisin-kexin type 9. 
Figure 3 Serum PCSK9 during hospitalisation in non-ST-elevation myocardial infarction (NSTEMI) stratified by 
hypercholesterolaemia. (A) Comparison of AUC during hospitalisation for PCSK9 in groups stratified by treatment and presence 
of hypercholesterolaemia (HC). Boxes represent median and 25th and 75th percentiles. (B) Serum PCSK9 during hospitalisation 
stratified by treatment and hypercholesterolaemia. The p values in (B) represent the group effects from the repeated measures 
analysis of variance (ANOVA). Circles represent geometric back-transformed estimated marginal means 95% CIs. AFN, 
afternoon; AUC, area under the curve; BL, baseline; EVE, evening; MO, morning; PCSK9, proprotein convertase subtilisin-kexin 
type 9. 
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and leucocyte count only in patients with hypercholes-
terolaemia in their medical history treated with tocili-
zumab. Experimental and clinical studies indicate that 
hypercholesterolaemia increases the number and athero-
genic potential of neutrophils and monocytes26 and we 
speculate that the attenuating effect of tocilizumab on 
PCSK9 in hypercholesterolaemia could be attributed to a 
decrease in the number of activated leucocytes that may 
influence PCSK9.
This substudy has several limitations such as a rather 
low number of patients and a wide distribution in the 
time from symptom onset to study drug administra-
tion. Moreover, PCSK9 levels are influenced by statins27 
which may disrupt its association with LDL-C and could 
explain the lack of association with lipids in our study. 
Thus, in our trial where the majority (90%) of patients 
were treated with statins, probing associations in statin-
naive patients was not possible although statin use was 
included in relevant analyses as a covariate. Finally, our 
study was not designed or powered to evaluate hypercho-
lesterolaemia and the group sizes were modest for this 
demographic.
The present study did not identify any association 
between markers of inflammation and PCSK9 during the 
acute phase response in NSTEMI or an effect of anti-IL-6 
therapy on PCSK9 levels. However, a modifying effect 
of tocilizumab on PCSK9 levels was observed in patients 
with hypercholesterolaemia in the medical history which 
may suggest that patients with a more atherogenic profile 
may benefit from anti-IL-6 therapy with regard to PCSK9. 
This hypothesis should be further tested in forthcoming 
larger studies targeting inflammation in patients with 
ACS, and if proven, it will further link inflammation and 
lipids as two interacting arms in the pathogenesis of CAD.
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